Article

Levels of Calcium Carbonate and Chlorine in Drinking Water May Contribute to Atopic Dermatitis in Infants

Author(s):

High calcium carbonate (CaCO3) and chlorine levels in public drinking water may be linked to an increased risk for developing atopic dermatitis.

High calcium carbonate (CaCO3) and chlorine levels in public drinking water may be linked to an increased risk for developing atopic dermatitis, according to a recent study released by the Journal of Allergy and Clinical Immunology.

The study evaluated just over 1,300 infants from the general population. Researchers collected data on CaCO3 and chlorine levels from the water sources serving their homes and neighborhoods. When the infants were enrolled, researchers also examined them for pre-existing atopic dermatitis as well as filaggrin (FLG), a gene mutation affecting the skin barrier.

The effects of CaCO3 and chlorine levels were strongly correlated, the study found. Three groups were examined: Low CaCO3/low chlorine, high CaCO3/low chlorine, and high CaCO3/high chlorine. Atopic dermatitis was more likely to develop in all three groups as compared to baseline.

As per the study: “Visible AD was more common in all 3 groups versus the baseline group: adjusted odds ratio (AOR) of 1.87 (95% CI, 1.25-2.80; P = .002) for the CaH/ClL group, AOR of 1.46 (95% CI, 0.97-2.21; P = .07) for the CaL/ClH, and AOR of 1.61 (95% CI, 1.09-2.38; P = .02) for the CaH/ClH group. The effect estimates were greater in children carrying FLG mutations, but formal interaction testing between water quality groups and filaggrin status was not statistically significant.”

The results suggest caution in providing municipal drinking water during infancy. While chlorine levels may still have an uncertain impact on AD at this time, it is clear that CaCO3 in drinking water can have a deleterious effect.

According to the researchers: “An intervention trial is required to see whether installation of a domestic device to decrease CaCO3 levels around the time of birth can reduce this risk.”

Related Videos
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Monica Kraft, MD: Discussing Phase 3b Findings on Albuterol/Budesonide for Asthma
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
© 2024 MJH Life Sciences

All rights reserved.